The DOAC Reversal Controversy ft Dr. Brian Gilbert

On this episode, we are joined by Brian Gilbert, PharmD, BCPS, BCCCP, David Moran, PharmD, and Jacob Reeder, PharmD, BCCCP to discuss andexanet alfa (Andexxa). We contrast the DOAC benefits that are popular among the ambulatory care community with the DOAC risks that the critical care teams often deal with. Dr. Gilbert leads the review of some concerns that many clinicians have with Andexxa. We recently had a paper publish in the American Journal of Emergency Medicine (Dr. Gilbert was the lead author). The name of the article and link can be found below: Throwing it in reverse: An update on reversal of oral factor Xa inhibitors https://doi.org/10.1016/j.ajem.2019.04.007   If you have any questions, reach out to us on any of the following: Mike - [email protected] Cole - [email protected] Instagram and other social media platforms - @corconsultrx This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.  

There are no comments yet.

Please log in to write the first comment.